Company description

DTIL or Precision BioSciences Inc. is a biotechnology company that specializes in developing and commercializing gene editing technologies. The company's proprietary technology, ARCUS, is a versatile platform that enables precise gene edits to be made in living cells with high efficiency and specificity. DTIL has a diverse portfolio of product candidates in various stages of development, including potential treatments for genetic disorders, oncology, and infectious diseases. The company is also leveraging its ARCUS technology to partner with other pharmaceutical companies to develop potentially life-changing therapies. DTIL has a strong financial position with a growing revenue stream, a dedicated team of experienced scientists and executives, and a commitment to revolutionize the field of gene editing and improve patient outcomes. Their innovative approach has garnered recognition and partnerships from leading healthcare organizations, solidifying their position as a leader in the biotechnology industry.